Squarepoint Ops LLC Acquires Shares of 175,735 Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Squarepoint Ops LLC bought a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 175,735 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hussman Strategic Advisors Inc. grew its stake in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $34,000. Jacobs Levy Equity Management Inc. purchased a new position in Marinus Pharmaceuticals during the 1st quarter valued at about $384,000. Finally, Values First Advisors Inc. boosted its stake in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

MRNS stock opened at $1.75 on Friday. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $11.26. The stock has a market capitalization of $96.13 million, a P/E ratio of -0.66 and a beta of 1.14. The business has a fifty day moving average price of $1.48 and a 200-day moving average price of $2.06.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the prior year, the company posted ($0.61) EPS. As a group, analysts anticipate that Marinus Pharmaceuticals, Inc. will post -1.93 earnings per share for the current year.

Analysts Set New Price Targets

MRNS has been the subject of a number of analyst reports. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Truist Financial reissued a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.